vonaprument

AssetAntibodyAlso ANX007

Inhibits classical complement pathway component C1q to protect synapses

Stage
Phase 3
Modality
Antibody
Target
Inflammation
Indications
1
Trials
1
Developers
1

Indications

1
  • Targets and what it contains5
  • Owner and partners1
  • Trials1
  • Evidence for its targets2
  • Aging relevance1

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Updated 7 Oct 2026 · 1 source

Assets